Ceftobiprole Medocaril Sodium

头孢比罗酯钠

Report date: 2026/03/31 20:00:21
NMEQIDP

Base Information

Drug NameCeftobiprole Medocaril Sodium
Drug Alias NameCeftobiprol medocarilo头孢吡普酯头孢比罗酯Ceftobiprolum medocarilumCeftobiprole medocaril +[19] 
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics > β-lactam antibiotics > Cephalosporins antibiotics
Mechanisms of ActionBacterial penicillin-binding protein inhibitors
TargetsBacterial penicillin-binding protein
Therapy Area/IndicationsHospital-acquired pneumoniaInfective EndocarditisCommunity Acquired Pneumonia +[21] 
Global Approved IndicationsHospital-acquired pneumoniaInfective EndocarditisCommunity Acquired Pneumonia +[10] 
Approved Indications in ChinaHospital-acquired pneumoniaCommunity Acquired Pneumonia
Original Approved Country/TerritoryCanada
Original Approved Date2008/06/26
Country/TerritoryBelgiumBulgariaCanada +[28] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBasilea Pharmaceutica
China Registration ClassN/A

Develop Information

Active CompaniesISTX LlcBasilea PharmaceuticaJSC Lancet +[5] 
Inactive CompaniesBasilea Pharmaceutica LtdJanssen-Cilag International NvBasilea Medical Ltd +[5] 
Active IndicationsHospital-acquired pneumoniaInfective EndocarditisCommunity Acquired Pneumonia +[11] 
Inactive IndicationsFeverObesityNeutropenia +[10] 

Other Information

ATC CodeJ01DI01
Related LinksWikipediaDrugBankKEGG